- Home
- ZVRA
as 07-26-2024 4:00pm EST
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | CELEBRATION |
| Market Cap: | 235.2M | IPO Year: | 2015 |
| Target Price: | $20.00 | AVG Volume (30 days): | 533.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.89 - $7.28 | Next Earning Date: | 08-12-2024 |
| Revenue: | $28,007,000 | Revenue Growth: | 198.84% |
| Revenue Growth (this year): | 7.22% | Revenue Growth (next year): | 188.76% |
Stock Insider Trading Activity of Zevra Therapeutics Inc. (ZVRA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Anderson Thomas | ZVRA | Director | Jul 16 '24 | Buy | $6.81 | 10,000 | $68,065.00 | 20,000 | SEC Form 4 |
| Bode John B | ZVRA | Director | Jul 12 '24 | Buy | $5.87 | 10,000 | $58,661.00 | 30,000 | SEC Form 4 |
Latest Zevra Therapeutics Inc. News
ZVRA Breaking Stock News: Dive into ZVRA Ticker-Specific Updates for Smart Investing
Simply Wall St.
14 days ago
Zevra Therapeutics Insider Confidence Rewarded, Stock Hits US$235m Market Cap
Zacks
16 days ago
Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
Zacks
17 days ago
Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?
BioPharma Dive
17 days ago
AbbVie names new R&D head; Arcutis eczema cream approved
Benzinga
17 days ago
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
GlobeNewswire
17 days ago
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
GlobeNewswire
a month ago
Zevra Therapeutics Expands Executive Leadership Team
Simply Wall St.
a month ago
Breakeven On The Horizon For Zevra Therapeutics, Inc. (NASDAQ:ZVRA)
Compare ZVRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZVRA Zevra Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.